TABLE 3.

Sustained and delayed response to erenumab in patients who continued with erenumab 70 mg (n = 42) and patients who escalated the dosage to 140 mg (n = 53)

	Patients who continued with 70 mg dose	Patients escalating dose to 140 mg	Total
Average reduction MMD in months 1–3 ≥50%
N	21	4	25
Sustained responders, n (%)	15 (71)	3 (75)	18 (72)
Average reduction MMD in months 1–3 <50%
N	21	49	70
Delayed responders, n (%)	5 (24)	11 (22)	16 (23)
Average reduction MMD in months 1–3 ≥30%
N	35	19	54
Sustained responders, n (%)	31 (89)	17 (89)	48 (89)
Average reduction MMD in months 1–3  <30%
N	7	34	41
Delayed responders, n (%)	1 (14)	7 (21)	8 (20)

N total = 95 (all patients who completed the 6‐month follow‐up period). Sustained responders = patients who achieved an average of ≥50% or ≥30% reduction in MMD during the first 3 months and during the last 3 months of treatment. Delayed responders = patients who did not achieve an average of ≥50% or ≥30% reduction in MMD during the first 3 months of treatment, but did during the last 3 months of treatment.

Abbreviation: MMD, monthly migraine days.